Cancer Res (2023) 83 (8_Supplement): LB031.

Abstract. Auristatins are a class of clinically validated payloads used extensively in antibody-drug conjugate (ADC) technology. There are currently 4 FDA approved ADCs utilizing the vedotin drug ...

Abstract. Lipid metabolism reprogramming modulates the tumor microenvironment (TME) and alters the function of immune cells, including tumor-infiltrating lymphocytes (TIL). Although lipids can enhance ...

1Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, China.

1Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.

Mitochondrial glutathione import via SLC25A39 supports breast cancer metastasis by linking glutathione availability to ATF4-driven integrated stress response signaling during early metastatic ...

Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on ...

Abstract. Binding of steroid hormones to their cognate receptors regulates the growth of most prostate and breast cancers. We hypothesized that CYP11A inhibition might halt the synthesis of all ...

The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...

Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...

1Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York. 2Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.